((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
accopy_reg
_reconstructor
p5
(cnltk.probability
FreqDist
p6
c__builtin__
dict
p7
(dp8
S'exploratory investig'
p9
I1
sS'pre-trial antihypertensive treatment dur'
p10
I1
sS'random'
p11
I2
sS'artery diseas'
p12
I1
sS'arm of the antihypertensive tri'
p13
I1
sS'pharmacologic treatment of particip'
p14
I1
sS'for particip'
p15
I1
sS'lipid low'
p16
I1
sS'of functional capac'
p17
I1
sS'coronary angioplasti'
p18
I1
sS'case-fatality for'
p19
I1
sS'post-event use of open-label diuret'
p20
I1
sS'chd event'
p21
I1
sS'high-density lipoprotein'
p22
I1
sS'clinical investig'
p23
I1
sS'chd death'
p24
I3
sS'secondary clinical outcom'
p25
I1
sS'edema'
p26
I2
sS'systolic hypertens'
p27
I1
sS'hg'
p28
I6
sS'cardiovascular caus'
p29
I1
sS'systolic blood'
p30
I1
sS'systolic dysfunct'
p31
I1
sS'continuous vari'
p32
I1
sS'analys'
p33
I1
sS'hf patient'
p34
I2
sS'risk'
p35
I3
sS'heart failure diagnostic criteria'
p36
I1
sS'public health'
p37
I1
sS'chronic obstructive pulmonary diseas'
p38
I1
sS'treatment of particip'
p39
I2
sS'coronary heart diseas'
p40
I1
sS'aventi'
p41
I1
sS'hf event'
p42
I13
sS'new'
p43
I2
sS'classification of functional capac'
p44
I1
sS'dose'
p45
I2
sS'hf diagnosi'
p46
I5
sS'medical management for hf'
p47
I1
sS'hf diagnos'
p48
I1
sS'hf ascertain'
p49
I1
sS'ad hoc'
p50
I1
sS'comparability of baselin'
p51
I1
sS'for diastolic hf'
p52
I2
sS'health quest'
p53
I1
sS'follow-up clin'
p54
I1
sS'hr'
p55
I1
sS'hf incid'
p56
I1
sS'validation of hf'
p57
I1
sS'statist'
p58
I3
sS'dsmb'
p59
I1
sS'cholesterol'
p60
I1
sS'ldl'
p61
I1
sS'prescription of open-label medicin'
p62
I1
sS'total mort'
p63
I1
sS'certif'
p64
I3
sS'clinical diagnos'
p65
I1
sS'doxazosin particip'
p66
I13
sS'revascular'
p67
I2
sS'medical management baselin'
p68
I1
sS'compens'
p69
I1
sS'fatal coronary heart diseas'
p70
I1
sS'nu-pharm'
p71
I1
sS'hospitalization for'
p72
I1
sS'cardiac diseas'
p73
I1
sS'diseas'
p74
I12
sS'pre-trial antihypertensive treat'
p75
I1
sS'fatal coronary heart'
p76
I1
sS'for chd ev'
p77
I2
sS'diastolic dysfunct'
p78
I2
sS'durat'
p79
I1
sS'nonfatal hf ev'
p80
I1
sS'arm'
p81
I3
sS'all-cause mort'
p82
I2
sS'clinic visit'
p83
I1
sS'the primary endpoint'
p84
I1
sS'compar'
p85
I2
sS'of chlorthalidon'
p86
I2
sS'ldl cholesterol'
p87
I1
sS'jtw'
p88
I1
sS'particip'
p89
I49
sS'systol'
p90
I1
sS'ventricular hypertrophi'
p91
I3
sS'non-hospitalized particip'
p92
I1
sS'pulmonary diseas'
p93
I2
sS'cardiovascular risk'
p94
I1
sS'staff'
p95
I2
sS'outpatient revascular'
p96
I2
sS'fatal ev'
p97
I1
sS'altern'
p98
I1
sS'documentation for qu'
p99
I1
sS'treatments for hf'
p100
I1
sS'patholog'
p101
I1
sS'heart classification functional class iii'
p102
I2
sS'national heart'
p103
I2
sS'ace-inhibitor'
p104
I8
sS'protocol-defined secondary clinical outcom'
p105
I1
sS'non-hospitalized hf'
p106
I1
sS'time-from-event-to-death analyses of particip'
p107
I1
sS'hypertensive particip'
p108
I1
sS'alternative antihypertensive drug'
p109
I1
sS'noninvas'
p110
I1
sS'post-hf event medical manag'
p111
I1
sS'statu'
p112
I3
sS'chlorthalidone for'
p113
I1
sS'hoc committe'
p114
I1
sS'randomization visit'
p115
I1
sS'drug'
p116
I7
sS'lvh'
p117
I3
sS'guidelin'
p118
I2
sS'trial'
p119
I5
sS'x-ray characteristic of hf'
p120
I1
sS'post-event use of'
p121
I1
sS'committe'
p122
I2
sS'ctc'
p123
I4
sS'studi'
p124
I3
sS'antihypertensive treatment of'
p125
I1
sS'medicin'
p126
I2
sS'lipid lowering treat'
p127
I1
sS'extremity edema'
p128
I1
sS'activ'
p129
I2
sS'sixth'
p130
I1
sS'classif'
p131
I1
sS'angiotensin-converting enzym'
p132
I1
sS'post-hf ev'
p133
I1
sS'allhat'
p134
I15
sS'the chlorthalidon'
p135
I1
sS'allhat manu'
p136
I1
sS'diagnostic standards of th'
p137
I1
sS'jnc vi'
p138
I1
sS'brd'
p139
I1
sS'fatal hf'
p140
I5
sS'novarti'
p141
I1
sS'dyspnea'
p142
I3
sS'fatal chd'
p143
I2
sS'ejection fraction information ascertain'
p144
I1
sS'pp'
p145
I5
sS'heart attack tri'
p146
I1
sS'chd'
p147
I7
sS'antihypertensive treat'
p148
I1
sS'prescript'
p149
I1
sS'visit'
p150
I2
sS'protocol-required document'
p151
I1
sS'risk factor for'
p152
I2
sS'two-third'
p153
I2
sS'two-thirds of'
p154
I1
sS'recommend'
p155
I2
sS'definition of hf'
p156
I1
sS'tachycardia'
p157
I1
sS'glaxo-smithklin'
p158
I1
sS'fraction review'
p159
I1
sS'adequaci'
p160
I1
sS'doxazosin treatment arm'
p161
I1
sS'antihypertensive drug'
p162
I1
sS'king pharmaceut'
p163
I1
sS'medical management baseline characteristics of chlorthalidon'
p164
I1
sS'chest x-ray characteristic of hf'
p165
I1
sS'validation of'
p166
I1
sS'lipid tri'
p167
I1
sS'skb'
p168
I2
sS'diastolic blood'
p169
I1
sS'antihypertensive treatment dur'
p170
I1
sS'allhat event report'
p171
I1
sS'lipoprotein'
p172
I1
sS'sbp'
p173
I2
sS'hf event report'
p174
I1
sS'iii'
p175
I2
sS'document'
p176
I9
sS'lung diseas'
p177
I1
sS'solvay'
p178
I1
sS'physician'
p179
I1
sS'classification of'
p180
I1
sS'endpoint'
p181
I10
sS'baseline characteristics of chlorthalidon'
p182
I1
sS'ejection fraction review'
p183
I1
sS'sixth report'
p184
I1
sS'non-cardiac caus'
p185
I1
sS'allhat endpoint'
p186
I2
sS'medication adher'
p187
I1
sS'calcium-channel block'
p188
I1
sS'mi'
p189
I3
sS'baseline characteristics baselin'
p190
I1
sS'treatments for'
p191
I1
sS'astrazeneca'
p192
I1
sS'outcom'
p193
I3
sS'bm'
p194
I5
sS'asymptomatic hypertens'
p195
I1
sS'cvd'
p196
I2
sS'hdl'
p197
I2
sS'documentation for'
p198
I1
sS'hypertrophi'
p199
I3
sS'hf outcom'
p200
I4
sS'heart'
p201
I7
sS'routine endpoints subcommitte'
p202
I1
sS'new york heart classification functional class'
p203
I2
sS'hospital discharg'
p204
I1
sS'routine endpoint'
p205
I1
sS'allhat criteria for hf'
p206
I1
sS'chlorthalidon'
p207
I11
sS'ordinary physical act'
p208
I1
sS'pharmacologic treatment of'
p209
I1
sS'upjohn'
p210
I1
sS'sankyo'
p211
I1
sS'in-hospit'
p212
I1
sS'event document'
p213
I2
sS'routine endpoints subcommittee qu'
p214
I1
sS'grant'
p215
I1
sS'ankle edema'
p216
I1
sS'medic'
p217
I3
sS'open-label beta-block'
p218
I1
sS'pharmacologic treat'
p219
I1
sS'chest x-ray'
p220
I1
sS'medical manag'
p221
I3
sS'coronary arteri'
p222
I1
sS'invasive tool'
p223
I1
sS'clinical outcom'
p224
I1
sS'bristol-my'
p225
I1
sS'monarch'
p226
I1
sS'hypertens'
p227
I2
sS'lowering treat'
p228
I1
sS'fraction information ascertain'
p229
I1
sS'alpha-adrenergic block'
p230
I1
sS'doxazosin arm'
p231
I3
sS'evid'
p232
I1
sS'two-thirds of ejection fract'
p233
I1
sS'allhat definition of hf'
p234
I1
sS'blood'
p235
I1
sS'risk factor for chd ev'
p236
I1
sS'catheter'
p237
I1
sS'time-from-event-to-death analyses of'
p238
I1
sS'phu'
p239
I5
sS'hypercholesterolemic pati'
p240
I1
sS'sy'
p241
I2
sS'appropri'
p242
I1
sS'of clinical ev'
p243
I1
sS'heart attack'
p244
I1
sS'sv'
p245
I2
sS'ambigu'
p246
I1
sS'caus'
p247
I4
sS'attack tri'
p248
I1
sS'gsk'
p249
I2
sS'allhat clinical tri'
p250
I1
sS'non-medical staff'
p251
I1
sS'se'
p252
I2
sS'clinical ev'
p253
I2
sS'st-t wave'
p254
I1
sS'allhat criteria for'
p255
I1
sS'risk factor for chd'
p256
I1
sS'categorical vari'
p257
I1
sS'probability of doxazosin showing benefit'
p258
I1
sS'diagnos'
p259
I2
sS'blocker'
p260
I2
sS'pharmacia'
p261
I1
sS'of hf diagnosi'
p262
I1
sS'jnc'
p263
I1
sS'report'
p264
I4
sS'lipid'
p265
I1
sS'pharmacologic manag'
p266
I1
sS'ad'
p267
I1
sS'for the primary endpoint'
p268
I1
sS'heart failure diagnost'
p269
I1
sS'monitoring board'
p270
I1
sS'death'
p271
I7
sS'monitor'
p272
I1
sS'validation of hf diagnosi'
p273
I1
sS'character'
p274
I1
sS'dysfunct'
p275
I4
sS'hf medic'
p276
I1
sS'characterization of'
p277
I1
sS'exercis'
p278
I1
sS'ventricular dysfunct'
p279
I1
sS'beta-block'
p280
I7
sS'hf particip'
p281
I2
sS'hospitalization for hf'
p282
I1
sS'ejection fract'
p283
I10
sS'baseline eligibility risk'
p284
I1
sS'diagnostic valid'
p285
I1
sS'relative risk of'
p286
I1
sS'open-label drug'
p287
I1
sS'treatment arm of the antihypertensive tri'
p288
I1
sS'nation'
p289
I3
sS'doxazosin treat'
p290
I2
sS'coronary artery diseas'
p291
I1
sS'discharg'
p292
I2
sS'bv'
p293
I1
sS'hg for'
p294
I1
sS'ljh'
p295
I1
sS'chlorthalidone for the primary endpoint'
p296
I1
sS'clinical pictur'
p297
I1
sS'atherosclerotic cardiovascular diseas'
p298
I3
sS'site staff'
p299
I1
sS'obstructive pulmonary diseas'
p300
I1
sS'post-hospit'
p301
I1
sS'total dos'
p302
I1
sS'manual'
p303
I1
sS'manifest'
p304
I1
sS'princip'
p305
I1
sS'allhat clin'
p306
I1
sS'mm hg'
p307
I3
sS'risk of hf'
p308
I1
sS'of particip'
p309
I3
sS'manag'
p310
I2
sS'cumulative ev'
p311
I1
sS'subset'
p312
I1
sS'chlorthalidone treat'
p313
I3
sS'allhat definit'
p314
I1
sS'of doxazosin'
p315
I2
sS'cabg'
p316
I3
sS'searl'
p317
I1
sS'antihypertens'
p318
I1
sS'shep'
p319
I1
sS'nhlbi'
p320
I1
sS'doxazosin'
p321
I8
sS'event'
p322
I20
sS'of the antihypertensive tri'
p323
I1
sS'baselin'
p324
I6
sS'variabl'
p325
I2
sS'affili'
p326
I1
sS'secondary endpoint'
p327
I2
sS'ecg abnorm'
p328
I1
sS'rr'
p329
I4
sS'post-ev'
p330
I2
sS'doxazosin treatment arm of'
p331
I1
sS'non-hospit'
p332
I1
sS'of open-label medicin'
p333
I1
sS'research'
p334
I1
sS'of doxazosin showing benefit'
p335
I1
sS'research gr'
p336
I1
sS'baseline pp'
p337
I2
sS'doxazosin showing benefit'
p338
I1
sS'atenolol'
p339
I1
sS'peripheral arterial diseas'
p340
I2
sS'smithkline beecham'
p341
I1
sS'open-label medicin'
p342
I2
sS'ecg'
p343
I2
sS'comparability of'
p344
I1
sS'of hf'
p345
I5
sS'time-from-event-to-death analys'
p346
I1
sS'clinical diagnosi'
p347
I1
sS'national committe'
p348
I1
sS'hf'
p349
I87
sS'ctc physician'
p350
I1
sS'validation exercis'
p351
I1
sS'ascertain'
p352
I3
sS'baseline sbp'
p353
I1
sS'death certif'
p354
I3
sS'allhat diagnostic criteria'
p355
I1
sS'criteria for hf'
p356
I1
sS'bp'
p357
I1
sS'benefit'
p358
I2
sS'investig'
p359
I2
sS'abbott'
p360
I1
sS'relative risk'
p361
I1
sS'fhhl'
p362
I1
sS'prescription of'
p363
I1
sS'diastolic hf'
p364
I1
sS'aha med'
p365
I1
sS'ace'
p366
I1
sS'pfizer'
p367
I1
sS'hg for th'
p368
I1
sS'quality control evalu'
p369
I1
sS'open-label ace-inhibitor'
p370
I2
sS'doxazosin treatment arm of the antihypertensive tri'
p371
I1
sS'cardiovascular ev'
p372
I1
sS'the antihypertensive tri'
p373
I1
sS'baseline characteristics of'
p374
I1
sS'mortal'
p375
I4
sS'event ascertain'
p376
I1
sS'baseline puls'
p377
I1
sS'squibb'
p378
I1
sS'for hf'
p379
I3
sS'primary endpoint'
p380
I4
sS'vi'
p381
I1
sS'aha'
p382
I1
sS'confirmatory ev'
p383
I1
sS'probability of'
p384
I1
sS'qualiti'
p385
I1
sS'diagnostic criteria'
p386
I3
sS'assess'
p387
I2
sS'clinical site staff'
p388
I1
sS'high-risk hypertensive particip'
p389
I1
sS'lung'
p390
I1
sS'class iii'
p391
I4
sS'statistical analys'
p392
I1
sS'bristol-myers squibb'
p393
I1
sS'treatment dur'
p394
I1
sS'management baseline characteristics of chlorthalidon'
p395
I1
sS'diuret'
p396
I8
sS'physical act'
p397
I2
sS'allhat criteria'
p398
I2
sS'outcome statu'
p399
I1
sS'pictur'
p400
I1
sS'question'
p401
I2
sS'capac'
p402
I2
sS'alternative antihypertens'
p403
I1
sS'confirmatory event document'
p404
I1
sS'ad hoc committe'
p405
I1
sS'new york'
p406
I2
sS'new york heart classification functional class iii'
p407
I2
sS'fraction'
p408
I6
sS'york heart classification functional class iii'
p409
I2
sS'of ejection fract'
p410
I1
sS'arterial diseas'
p411
I2
sS'adher'
p412
I1
sS'clinical sit'
p413
I1
sS'copd'
p414
I1
sS'open-label diuret'
p415
I5
sS'beecham'
p416
I1
sS'nonfatal hf'
p417
I2
sS'criteria'
p418
I4
sS'characterization of clinical ev'
p419
I1
sS'echocardiogram'
p420
I3
sS'new york heart classif'
p421
I2
sS'public health quest'
p422
I1
sS'consult'
p423
I1
sS'risk factor for diastolic hf'
p424
I1
sS'patient'
p425
I3
sS'cardiovascular diseas'
p426
I4
sS'heart failure diagnosi'
p427
I1
sS'heart diseas'
p428
I1
sS'symptom'
p429
I3
sS'chest x-ray characteristic of'
p430
I1
sS'king'
p431
I1
sS'two-component clinical tri'
p432
I1
sS'of open-label diuret'
p433
I2
sS'hg for the chlorthalidon'
p434
I1
sS'beta-blocker use post-ev'
p435
I1
sS'diagnostic standards of'
p436
I1
sS'open-label beta-blocker use post-ev'
p437
I1
sS'minut'
p438
I1
sS'medical management for'
p439
I1
sS'x-ray'
p440
I1
sS'antihypertensive treatment of particip'
p441
I1
sS'chlorthalidone for th'
p442
I1
sS'ab'
p443
I2
sS'biovail'
p444
I1
sS'evalu'
p445
I2
sS'hf outcome statu'
p446
I1
sS'antihypertensive tri'
p447
I1
sS'diagnosi'
p448
I8
sS'chlorthalidone particip'
p449
I7
sS'expir'
p450
I1
sS'angioplasti'
p451
I1
sS'case-fatality for particip'
p452
I1
sS'event report'
p453
I3
sS'az'
p454
I3
sS'for the chlorthalidon'
p455
I1
sS'clinical tri'
p456
I2
sS'probabl'
p457
I1
sS'double-blind'
p458
I1
sS'maximum dos'
p459
I1
sS'allhat ev'
p460
I2
sS'treatment'
p461
I12
sS'medical management baseline characteristics of'
p462
I1
sS'accuraci'
p463
I1
sS'baseline characteristics of doxazosin'
p464
I1
sS'lost-to-follow-up'
p465
I1
sS'wcc'
p466
I1
sS'valid'
p467
I4
sS'confirmatory evid'
p468
I1
sS'pulmonary patholog'
p469
I1
sS'np'
p470
I2
sS'nonfatal mi'
p471
I2
sS'follow-up clinic visit'
p472
I1
sS'tool'
p473
I1
sS'manifestations of hf'
p474
I1
sS'board'
p475
I1
sS'exertional dyspnea'
p476
I1
sS'principal investig'
p477
I1
sS'manifestations of'
p478
I1
sS'ascvd'
p479
I3
sS'post-diagnosis pharmacologic manag'
p480
I1
sS'study criteria'
p481
I1
sS'new york heart'
p482
I2
sS'eligibility risk'
p483
I2
sS'study guidelin'
p484
I2
sS'classification functional class iii'
p485
I2
sS'doxazosin treatment arm of th'
p486
I1
sS'allhat definition of'
p487
I1
sS'enzym'
p488
I1
sS'diagnostic standard'
p489
I1
sS'analyses of particip'
p490
I1
sS'two-fold'
p491
I1
sS'eject'
p492
I1
sS'util'
p493
I2
sS'relative risk of hf'
p494
I1
sS'hf hospit'
p495
I1
sS'km'
p496
I2
sS'hospit'
p497
I6
sS'abnorm'
p498
I1
sS'event medical manag'
p499
I1
sS'hf statu'
p500
I2
sS'review'
p501
I1
stp502
Rp503
(dp504
S'_N'
p505
I1041
sS'_max_cache'
p506
NsS'_item_cache'
p507
NsS'_Nr_cache'
p508
Nsbtp509
.